Transfusion protocol for patients with sickle hemoglobinopathies at Children's National Medical Center

Immunohematology

Volumn 28, Issue 1, 2012, Pages 13-16

  Fasano, Ross M ^a,b   Paul, Wendy ^a,b   Siegal, Elizabeth ^a   Luban, Naomi L C ^a,b  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BLOOD DONOR; BLOOD GROUP TYPING; BLOOD TRANSFUSION; CLINICAL PROTOCOL; HEALTH CARE POLICY; HUMAN; PEDIATRIC HOSPITAL; PHENOTYPE; PRIORITY JOURNAL; SICKLE CELL ANEMIA;

AFRICAN AMERICANS; ANEMIA, SICKLE CELL; BLOOD DONORS; BLOOD GROUP ANTIGENS; BLOOD GROUP INCOMPATIBILITY; CHILD; DISTRICT OF COLUMBIA; ERYTHROCYTE TRANSFUSION; HUMANS; ISOANTIBODIES; PROGRAM EVALUATION;

EID: 84862512649     PISSN: 0894203X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. McPherson ME, Anderson AR, Castillejo MI, et al. HLA alloimmunization is associated with RBC antibodies in multiply transfused patients with sickle cell disease. Pediatr Blood Cancer 2010;54:552-8.
2. Rosse WF, Gallagher D, Kinney TR, et al. Transfusion and alloimmunization in sickle cell disease. The Cooperative Study of Sickle Cell Disease. Blood 1990;76:1431-7.
3. Adams RJ, Brambilla D Optimizing Primary Stroke Prevention in Sickle Cell Anemia (STOP 2) Trial Investigators. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med 2005;353:2769-78.
4. Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med 1998;339:5-11.
5. Casella JF, King AA, Barton B, et al. Design of the Silent Cerebral Infarct Transfusion (SIT) Trial. Pediatr Hematol Oncol 2010;27:69-89.
6. Ware RE, Schultz WH, Yovetich N, et al. Stroke With Transfusions Changing to Hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload. Pediatr Blood Cancer 2011;57:1011-17.
7. Aygun B, Padmanabhan S, Paley C, Chandrasekaran V. Clinical significance of RBC alloantibodies and autoantibodies in sickle cell patients who received transfusions. Transfusion 2002;42:37-43.
8. Castellino SM, Combs MR, Zimmerman SA, Issitt PD, Ware RE. Erythrocyte autoantibodies in paediatric patients with sickle cell disease receiving transfusion therapy: frequency, characteristics and significance. Br J Haematol 1999;104:189-94.
9. Smith-Whitley K. Alloimmunization in patients with sickle cell disease. In: Herman JH, Manno CS, eds. Pediatric Transfusion Therapy. Bethesda, MD: AABB Press; 2003:249-82.
10. Castro O, Sandler SG, Houston-Yu P, Rana S. Predicting the effect of transfusing only phenotype-matched RBCs to patients with sickle cell disease: theoretical and practical implications. Transfusion 2002;42:684-90.
11. Lasalle-Williams M, Nuss R, Le T, et al. Extended red blood cell antigen matching for transfusions in sickle cell disease: a review of a 14-year experience from a single center (CME). Transfusion 2011;51:1732-9.
12. Vichinsky EP, Luban NL, Wright E, et al. Prospective RBC phenotype matching in a stroke-prevention trial in sickle cell anemia: a multicenter transfusion trial. Transfusion 2001;41:1086-92.